<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850122</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00012011</org_study_id>
    <secondary_id>1K23HD060040-01</secondary_id>
    <nct_id>NCT00850122</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates</brief_title>
  <official_title>An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Brian Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I open label multi-dose study to investigative the pharmacokinetics and
      safety of cefazolin in infants &lt;121 days of age and &lt; 28 weeks gestation with suspected
      sepsis. There will be two cohorts of 6 infants each: 1) &gt;48 hours of age and ≤28 days and 2)
      &gt;28 days of age and &lt;121 days of age. The study requires administration of the study drug
      over 2 days followed by 1 week of safety monitoring. Six 200 µL pK samples will be obtained
      over the 2 days of drug administration. The risks are reasonable vs. the benefits and have
      been minimized appropriately. There may be benefit to the subjects (administration of
      empirical antimicrobial therapy), and information from the study may benefit a large number
      of other infants in whom the drug is currently being administered despite the lack of PK data
      in this population.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cefazolin pharmacokinetics including half life, clearance, and volume of distribution</measure>
    <time_frame>Dose 1 and Dose 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>7 days following last dose of cefazolin</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Sepsis</condition>
  <condition>Prematurity</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Number of Infants
≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefazolin</intervention_name>
    <description>Cefazolin dosing - administered for 48 hours Dosage
≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8</description>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; 28 weeks gestation at birth

          -  &gt; 48 hours and &lt;121 days of age at the time of study drug administration

          -  One of the following:

               -  Suspected systemic infection

               -  Receiving cefazolin for prophylaxis

               -  Receiving cefazolin treatment of a systemic infection

        Exclusion Criteria:

          -  History of anaphylaxis attributed to a β-lactam

          -  Exposure to cefazolin in the month prior to study

          -  Serum creatinine &gt; 1.7 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Phillip Brian Smith</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

